Telehealth company Hims & Hers said late Monday in an earnings update that it plans to launch a generic version of Novo ...

Semaglutide, the scientific name for Novo’s GLP-1 diabetes drug Ozempic and obesity drug Wegovy, has been on the shortage ...

SGLT2 inhibitors and GLP-1 receptor agonists exhibit renoprotective effects in patients with CKD with and without diabetes.

Novo Nordisk chief financial officer Karsten Munk Knudsen said on Wednesday the company was aware of reports of 10 deaths and 100 hospitalisations of people who had taken compounded copies of its ...

Grapefruit can interact with many medications, potentially affecting the way they work or increasing side effects. Some of ...

It is a sign that Novo Nordisk’s efforts to ramp up the supply of those drugs are starting to pay off, as demand continues to ...

Those market dynamics will again be in focus when Novo reports results for its diabetes drug Ozempic and weight-loss ... get ...

After years in shortage, weight loss and diabetes drugs Ozempic and Wegovy are now considered to be “available” by the Food ...

Online health platforms continue to advertise access to copycat versions of blockbuster weight-loss drugs Wegovy and Zepbound ...

People with Type 2 diabetes taking semaglutide appeared to have a significantly lower risk of developing Alzheimer's compared ...

These drugs are collectively known as GLP-1 agonists because they mimic the body’s natural hormone GLP-1, which regulates ...

The diabetes and weight loss medications Ozempic and Wegovy are now considered to be available after more than two years of ...